Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Telo Genomics Corp (OP: TDSGF )

0.1064 UNCHANGED
Last Price Updated: 2:30 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.1064
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1064
Today's Range 0.1064 - 0.1064
52wk Range 0.0795 - 0.2372
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
EXCLUSIVE: Telo Genomics' Smoldering Multiple Myeloma Prognostic Test Predicts Risk Of Disease Progression, Study Shows
American Journal of Hematology accepts Telo Genomics' study on TeloViewSMM, a prognostic test for smoldering multiple myeloma. The test showed 85% positive and 73% negative predictive values, offering... 
Via Benzinga
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia

Performance

YTD
-44.50%
-44.50%
1 Month
-35.12%
-35.12%
3 Month
-18.15%
-18.15%
6 Month
-17.52%
-17.52%
1 Year
-44.03%
-44.03%

More News

Read More
Telo Genomics Completes International Standards Organization ("ISO") 15189 Final Accreditation
Via Newsfile
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
From FN Media Group LLC
Via GlobeNewswire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
Via FinancialNewsMedia
Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM – An Important Commercial Milestone Achieved
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting
Via FinancialNewsMedia
Telo Genomics Announces Achieving Interim Results from Smouldering Myeloma Clinical Study
Via Newsfile
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.